论文部分内容阅读
运用转基因技术将参与甲状腺碘代谢的基因转染到肿瘤中,可介导放射性碘治疗肿瘤。涉及的基因有钠-碘转运体基因、甲状腺过氧化物酶基因及甲状腺特异转录因子等。在目的基因前加入组织特异性启动子(增强子),诱导下游目的基因定向表达于肿瘤组织,可将放射性碘用于多种肿瘤的治疗。转基因后的肿瘤细胞摄碘能力明显增强,放射性碘对转基因后的肿瘤治疗有效,其存在的主要问题是碘在肿瘤细胞(组织)中滞留时间较短,影响了放射性碘的疗效2。11At和188Re也可被钠-碘转运体转运,有望成为治疗具有摄碘能力的肿瘤的新核素。
The use of genetically modified technology will be involved in thyroid iodine metabolism of genes transfected into tumors, can mediate radioactive iodine treatment of tumors. The genes involved are sodium-iodide transporter gene, thyroid peroxidase gene and thyroid-specific transcription factor. Tissue-specific promoters (enhancers) are added before the gene of interest to induce targeted expression of downstream target genes in the tumor tissue, and radioiodine can be used for the treatment of various tumors. Tumor cells after transfection of iodine was significantly enhanced ability to radioactive iodine treatment of genetically modified cancer effective, its main problem is the retention of iodine in tumor cells (tissue) shorter retention time, affecting the efficacy of radioactive iodine 2.11At and 188Re is also transported by sodium-iodide transporters and is expected to become a new nuclide for the treatment of tumors with iodine-uptake capacity.